Expanding Markets ER-REBOA and related catheter technologies are expanding from trauma into cardiac arrest, postpartum hemorrhage, interventional radiology, perioperative, and pre-hospital settings, with adoption already over 250 hospitals. This suggests cross-selling opportunities into adjacent high-need areas and expanding use cases in both US and international markets.

Clinical Leadership Recent additions to the clinical leadership and advisory team, including a Medical Director on the Clinical Advisory Board, indicate an emphasis on clinical validation and endorsement. Leverage these relationships to co-create training programs, CME activities, and case studies that accelerate clinician adoption.

Commercial Strength Significant executive and commercialization hires in 2020–2023, including Chief Commercialization Officer and a new CEO, signal a strategic push to scale field sales, distributor networks, and hospital adoption. Target hospitals and trauma centers with formal rollout plans and procurement pathways.

Product Pipeline Introduction of the pREBOA-PRO and ER-REBOA PLUS demonstrates ongoing product innovation and the ability to offer enhanced partial-use and advanced occlusion capabilities. Opportunities exist to position upgraded devices for trauma programs, ERs, and critical care teams seeking improved control and outcomes.

Strategic Partnerships Affiliations with trauma research and innovative healthcare coalitions, plus active global expansion, present openings for distribution partnerships, joint training initiatives, and co-marketed clinical studies with major trauma centers and emergency medicine networks to accelerate market penetration.